Post-earnings recap
Reported
Fri, Nov 16, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Kodiak Sciences saw a positive stock reaction, rising nearly 10%. Investors may be encouraged by management's focus on clinical trials and product pipeline, indicating potential future growth. The lack of revenue data and guidance suggests uncertainty, but the stock's increase reflects optimism in the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their clinical programs. They emphasized the importance of their research and development efforts.
Management expressed confidence in their ongoing clinical trials.
They highlighted the potential of their pipeline products.